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Abstract: Rivaroxaban (Xarelto®) is a member of a new class of oral, direct (antithrombin-
independent) factor Xa inhibitors, which restrict thrombin generation both in vitro and in vivo. 
After oral administration the absorption is near 100%, the bioavailability is near 80%, and the 
elimination half-life is 5–9 hours with mixed excretion via the renal and fecal/biliary routes. 
The pharmacokinetics of rivaroxaban are predictable and consistent with a rapid onset of anti-
thrombotic action within 2 hours after administration. Phase II clinical studies have been carried 
out in patients undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA) and 
a dose of 10 mg once daily for thromboprophylaxis was selected for further clinical develop-
ment. The results of the phase III studies showed a signiﬁ  cantly better antithrombotic efﬁ  cacy 
of rivaroxaban compared with enoxaparin both in the short term (10–14 days) in TKA patients 
and long term (35 ± 4 days) in THA patients with a comparable safety. Symptomatic thrombo-
embolic events were also signiﬁ  cantly reduced with rivaroxaban. Liver enzyme elevation was 
seen in patients treated with rivaroxaban, but there was no indication of an increased risk of 
liver toxicity compared with enoxaparin. In conclusion, rivaroxaban is a potent and safe new 
compound for antithrombotic prophylaxis in orthopedic surgery.
Keywords: deep vein thrombosis, oral direct factor Xa inhibitor, pulmonary embolism, rivar-
oxaban, thromboprophylaxis, total hip arthroplasty, total knee arthroplasty
Introduction
Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are operations with 
a high risk of venous thromboembolic (VTE) complications and in the latest ACCP 
guidelines it is recommended to use prophylaxis with a low-molecular-weight heparin 
(LMWH), fondaparinux (a synthetic pentasaccharide) or adjusted-dose vitamin K 
antagonist (VKA) for at least 10 days after operation and to give extended prophylaxis 
for 28–35 days after THA and hip fracture surgery (Geerts et al 2004). Administration 
of LMWH and fondaparinux is subcutaneous and therefore these drugs are less suited 
for self-administration after discharge. Extended prophylaxis with enoxaparin after 
THA was cost-effective only when more than half of all patients were able to self-inject 
their treatment (Bergqvist and Johnsson 1999). Although administered orally, VKA is 
inconvenient to use due to the narrow therapeutic window and the need for repeated 
dose adjustments requiring laboratory monitoring. Thus, it has long been hoped that 
more convenient oral antithrombotic drugs would be discovered. The ﬁ  rst step in this 
direction was when ximelagatran, an oral direct thrombin inhibitor, was introduced on 
the market. However, when safety reports from patients on extended prophylaxis after 
major orthopedic surgery indicated a risk of liver toxicity it was eventually withdrawn 
(Kenne et al 2008). Since then several other oral anticoagulant compounds have been 
developed and they are currently undergoing clinical evaluation in orthopedic surgery Vascular Health and Risk Management 2008:4(4) 856
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(Eriksson et al 2005, 2007a; Lassen et al 2007a). One of these 
is rivaroxaban (Xarelto®; Bayer HealthCare), a direct factor 
Xa (FXa) inhibitor (Perzborn et al 2005).
Review of pharmacology, 
mode of action, pharmacokinetics
of factor Xa inhibitors
Activation of factor X to FXa initiates the conversion of pro-
thrombin to thrombin which leads to conversion of ﬁ  brinogen 
to ﬁ  brin and eventually clot formation (Figure 1). An invasive 
operative procedure cannot be performed without tissue 
damage resulting in release of tissue factor (TF). Orthopedic 
surgery due to surgical damage to bone is especially prone 
to TF release because bone marrow is rich in TF (Dahl et al 
1995). In conjunction with factor VIIa, TF activates FXa 
directly (the extrinsic pathway) or via propagation of the 
tenase complex (factor VIIIa + factor IXa) on an activated 
platelet membrane (the intrinsic pathway) (Mann et al 2003). 
The prothrombinase complex is then formed on the platelet 
surface and incorporation of FXa into this complex increases 
the rate of thrombin generation tremendously. The thrombin-
generating efﬁ  cacy of the prothrombinase complex is much 
more pronounced than that of free FXa (Mann et al 1998; 
Rauch and Nemerson 2000; Mann et al 2003a). Thus, FXa is 
the pivotal point in the coagulation cascade because it can be 
activated both by the extrinsic and the intrinsic pathways; fur-
thermore the only function of FXa in the coagulation process 
is to promote coagulation and to amplify the events. Thus, it 
has been estimated that one molecule of FXa catalyzes the 
formation of ~1000 thrombin molecules (Mann et al 2003b). 
In the design of new antithrombotic drugs it therefore seems 
attractive to target the mode of action towards inhibition of 
FXa. Unfractionated heparin (UFH) and LMWH are indirect 
FXa inhibitors because they inhibit FXa by potentiation of 
the natural inhibitory action of antithrombin (AT) that is an 
endogeneous plasma protein. In addition especially UFH also 
has an inhibitory action on several other coagulation factors 
among which factor IIa is the most important. Fondaparinux 
is a synthetic pentasaccharide with the same mode of action 
as UFH and LMWH, but in contrast to those it acts solely by 
the antithrombin-mediated inhibition of FXa (Samama and 
Gerotziafas 2003). On the contrary, direct FXa inhibitors, 
including rivaroxaban, do not need AT to exert their inhibi-
tory action on FXa, because they are able to bind directly to 
the active site of FXa, thereby preventing interaction with 
its substrates. As a consequence the direct FXa inhibitors 
are able to inhibit both free FXa and FXa bound in the pro-
thrombinase complex (Perzborn 2005) (Figure 1).
Rivaroxaban belongs to a new group of oral direct FXa 
inhibitors. The chemical structure is shown in Figure 2 and 
Figure 1 Schematic represention of the coagulation cascade with indication of mechanism of action of direct FXa inhibitors. Reproduced with permission from Bayer 
HealthCare.
Factor Xa
Extrinsic Intrinsic
pathway pathway
Phospholipids
FVa - FXa
Ca2+ Prothrombinase
Prothrombin
complex
Thrombin
THROMBIN ACTIVITY
Fibrin Fibrinogen
Direct
Factor Xa
inhibitors
P
H
A
S
E
P
H
A
S
E
P
H
A
S
E
P
R
O
P
A
G
A
T
I
O
N
I
N
T
I
A
T
I
O
NVascular Health and Risk Management 2008:4(4) 857
VTE prevention with rivaroxaban in orthopedic surgery
pharmacologic features are listed in Table 1. The absorption 
after oral intake is near 100%. Cmax is reached within 2–4 
hours (Kubitza et al 2005a) and is slightly enhanced by food 
intake, irrespective of type of food (Kubitza et al 2006a). 
The bioavailability is near 80% (Kubitza et al 2005b). The 
elimination is unchanged via the renal and the fecal/biliary 
routes (Kubitza and Haas 2006).
Preclinical studies
In vitro studies have shown that rivaroxaban can inhibit 
both free FXa and FXa bound in the prothrombinase com-
plex more potently in human and rabbit plasma than in rat 
plasma. The antithrombotic effect of rivaroxaban has also 
been studied in vivo in rat and rabbit models. In a rat venous 
stasis model rivaroxaban reduced venous thrombosis in 
a dose-dependent fashion and was able to reduce arterial 
thrombus formation in an arteriovenous shunt in both rats 
and rabbits. When given in antithrombotic doses (3 mg per 
kg po) rivaroxaban did not affect bleeding time signiﬁ  cantly 
in rats or rabbits (Perzborn et al 2005).
The pharmacokinetic and pharmacodynamic features of 
rivaroxaban were studied in a number of studies in healthy 
human subjects. In a single-dose escalation study, with 
placebo control, doses of rivaroxaban of 5–80 mg orally 
were studied in 108 male subjects. The study showed a dose-
dependent inhibition of FXa and an additional prolongation 
of prothrombin time (PT), which correlated with the plasma 
concentration of rivaroxaban. The new drug was well toler-
ated and there was no increased risk of bleeding compared 
with placebo (Kubitza et al 2005b). In a placebo-controlled 
multiple dose escalation study, rivaroxaban doses of 5 mg 
once, twice, and thrice daily, and 10 mg, 20 mg, and 30 mg 
twice daily were administered orally on days 0 and 3–7. The 
study showed no clinically relevant inﬂ  uence on bleeding 
time after treatment for 7 days and there were no signs of 
accumulation at any dose. A dose-dependent prolongation 
of PT, activated partial thromboplastin time (aPTT), and 
HepTest to a similar extent to inhibition of FXa were seen, 
and it was suggested that the inhibition of the FXa activity 
of rivaroxaban can be monitored by these clotting tests or 
by measurement of FXa alone (Kubitza 2005a). None of the 
studies showed problems with tolerability or safety with any 
dose or dosing frequency of rivaroxaban.
A number of interaction studies in healthy subjects 
between rivaroxaban and commonly used drugs such as ace-
tyl salicylic acid (ASA) and nonsteroid acetylsalicylic acids 
(NSAID) were performed. Concomitant use of ASA in 500 
mg and 100 mg doses and rivaroxaban at doses between 5 mg 
and 80 mg did not show any clinically relevant interaction 
(Kubitza et al 2006b). Rivaroxaban together with NSAID 
(naproxen) signiﬁ  cantly increased bleeding time compared 
with rivaroxaban alone, but it was not clinically relevant 
(Kubitza et al 2007a). A comparative placebo-controlled 
study in 50 subjects treated with rivaroxaban or moxiﬂ  oxacin 
(positive control) showed no prolongation of the QT-inter-
val of rivaroxaban, and thus there is no need to monitor the 
QT-interval routinely in patients treated with rivaroxaban 
(Kubitza et al 2008).
With a half-life of 5–9 hours it would be expected that 
rivaroxaban should be administered at least twice daily to 
be effective. However, a crossover placebo-controlled study 
in which 12 healthy subjects received single oral doses of 
5–30 mg of rivaroxaban showed that the endogenous throm-
bin potential was dose-dependently reduced by more than 
80%, compared with baseline, and that the prothrombinase-
induced clotting time in platelet-rich plasma was prolonged 
more than 1.8 times, both effects having a duration of 
24 hours (Graff et al 2007). Thus, this would support a con-
cept of once-daily administration. The clinical impact of these 
ﬁ  ndings was further explored in the phase II program.
Phase II program (dose ﬁ  nding)
A series of dose-ranging studies was performed in patients 
undergoing THA or TKA and an overview of the results of 
these studies is given in Table 2. The ﬁ  rst proof-of-principle 
study, which included patients undergoing THA, was an open-
label, randomized study to assess the efﬁ  cacy and safety of 
different doses of rivaroxaban relative to a standard regimen of 
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Figure 2 Chemical structure of rivaroxaban. Reproduced with permission from 
Bayer HealthCare.
Table 1 Pharmacologic features of rivaroxaban taken orally
Absorption  ∼100%
Cmax 2–4  hours
t½ 5–9  hours
Bioavailability  ∼80%
Elimination renal
 fecal/biliaryVascular Health and Risk Management 2008:4(4) 858
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enoxaparin (Eriksson et al 2007b). Rivaroxaban was given as 
tablets in doses of 2.5 mg, 5 mg, 10 mg, 20 mg, and 30 mg twice 
daily and 30 mg once daily, started 6–8 h after surgery; enoxa-
parin was given by subcutaneous injection of 40 mg once daily 
started on the evening before surgery. The investigators were 
blinded to the dose of rivaroxaban, but not to the type of prophy-
laxis (rivaroxaban vs enoxaparin). The treatment continued for 
5–9 days at which time a bilateral venography was performed to 
diagnose asymptomatic deep vein thrombosis (DVT); in cases 
of symptoms of DVT or pulmonary embolism (PE) during the 
study objective conﬁ  rmation of the event was requested. The 
efﬁ  cacy results with rivaroxaban were comparable with that 
obtained with enoxaparin, but with a ﬂ  at dose response. The 
incidences of major bleeding were dose-dependent and at an 
acceptable level. In patients treated with rivaroxaban 30 mg 
once daily the efﬁ  cacy result was comparable with the result 
in the enoxaparin group (15.1% vs16.8%) and the incidence 
of major bleeding (4.5%) was within the expected range, 
which was the ﬁ  rst indication that once-daily administration of 
rivaroxaban could be feasible (Table 2). The next two studies 
to follow were randomized, double-blind studies in THA or 
TKA patients, respectively (Turpie et al 2005; Eriksson et al 
2006a). The dose regimens of rivaroxaban were 2.5 mg, 5 mg, 
10 mg, 20 mg, and 30 mg administered orally twice daily started 
6–8 h after surgery and the comparator was again subcutane-
ous injections of enoxaparin, 40 mg once daily started on the 
evening before surgery in the THA study, and 30 mg twice daily 
started 12–24 h after surgery in the TKA study. The duration of 
the treatment and timing of venography was the same as for the 
previously described study. The efﬁ  cacy results obtained in both 
studies again showed a ﬂ  at dose-response for rivaroxaban with 
incidences in the different dose groups that were comparable 
with the enoxaparin group in the individual study. The inci-
dences of VTE in both treatment arms of the TKA study were 
much higher (25.4%–40.4% in the rivaroxaban groups and 
44.3% in the enoxaparin group) than those seen in the THA 
study (7%–18% in the rivaroxaban groups and 17% in the 
enoxaparin group) (Table 2), which is not surprising after knee 
surgery based on previous reports (Gillespie et al 2000; Geerts 
et al 2004). The safety results with rivaroxaban were also at a 
comparable level with enoxaparin and clearly dose-dependent 
(Table 2). A pooled analysis of the two studies showed that 
total daily doses of rivaroxaban of 5–20 mg had the most 
favorable balance between antithrombotic efﬁ  cacy and safety 
compared with enoxaparin (Fisher et al 2007). The last study 
in the phase II program was performed in patients undergoing 
THA, and in contrast to the previous studies it was decided 
that rivaroxaban was to be administered once daily in all dose 
groups (Eriksson et al 2006b). The following once-daily doses 
of rivaroxaban were studied: 5 mg, 10 mg, 20 mg, 30 mg, and 
40 mg started 6–8 h after surgery, and for the comparator arm 
enoxaparin 40 mg injected subcutaneously once daily started 
on the evening before surgery was chosen. Treatment duration 
and timing of venography was the same as for the previously 
described studies. The primary efﬁ  cacy end-point was observed 
in 6.4%–14.9% of patients in the different rivaroxaban dose 
groups, without any dose relation, and in 25.2% of the enoxa-
parin group; however, the study was not powered to show any 
Table 2 Overview of the results of the four clinical studies in phase II (per-protocol data)
Design Doses (mg) N Efﬁ  cacya (%) Safetyb (%)
   riva enox riva enox riva enox riva enox
THA
(Eriksson et al 2007b)
Open,
randomized
2.5, 5, 10, 
20, 30 bidc 
30 odc
40 odd 359 107 10.2–23.8 
15.1
16.8 2.5–10.8
4.5
0
THA
(Eriksson et al 2006a)
Double-blind, 
randomized
2.5, 5, 10, 
20, 30 bidc
40 odd 442 106 7–18 17 0.8–5.4 1.5
TKA
(Turpie et al 2005)
Double-blind, 
randomized
2.5, 5, 10, 
20, 30 bidc
30 bide 296 70 25.4–40.4 44.3 1–7.5 1.9
THA
(Eriksson et al 2006b)
Double-blind, 
randomized
5, 10, 20, 
30, 40 od
40 odd 511 107 6.4–14.9 25.2 0.7–5.1 1.9
aPrimary efﬁ  cacy end-point was the composite of the incidence of any deep vein thrombosis (proximal and/or distal), nonfatal symptomatic, objectively conﬁ  rmed pulmonary 
embolism and all cause deaths.
bPrimary safety end-point was the incidence of major bleeding (according to preset criteria) starting after the ﬁ  rst postoperative dose of study drug, but no later than 2 days 
after the last dose of study drug.
cStarted 6–8 h after surgery (tablets).
dStarted on the evening before surgery (injected subcutaneously).
eStarted 12–24 h after surgery (injected subcutaneously).
Abbreviations: THA, total hip arthroplasty; TKA, total knee arthroplasty; riva, rivaroxaban; enox, enoxaparin.Vascular Health and Risk Management 2008:4(4) 859
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statistical signiﬁ  cance (Table 2). The primary safety end-point 
was observed in 0.7%–5.1% of patients in the rivaroxaban 
groups, with a signiﬁ  cant dose-dependency, compared with 
1.9% in the enoxaparin group. When compared with the safety 
results of the previous study in THA using twice-daily dosing of 
rivaroxaban the results did not differ much for total daily doses 
of 5 mg (0.8% vs 2.3%), 10 mg (0.7% vs 2.2%), 20 mg (4.3% 
vs 2.3%), and 40 mg (5.1% vs 4.5%) (Eriksson et al 2006a). 
Thus, once-daily dosing of rivaroxaban did not seem to increase 
the risk of bleeding compared with twice-daily dosing.
In the entire phase II program all adverse reactions 
observed in the treatment groups were registered. To follow 
the liver function repeated measurements of liver amino-
transferase levels such as alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) and bilirubin levels up 
to 7 days after the last dose of study medication were 
performed. In the second THA study in phase II (Eriksson 
et al 2006a) ALT or AST levels 3 times the upper limit 
of normal (ULN) occurred in 11.2% and 8.8% of patients 
in the enoxaparin group compared with 3.9%–6.4% and 
3.3%–8.3%, respectively, in the rivaroxaban groups. In 
the phase II TKA study (Turpie et al 2005), elevated levels 
of ALT and AST (3x ULN) and of bilirubin (2x ULN) 
were seen in 4 patients in the rivaroxaban groups. Two of 
these patients with elevated ALT and bilirubin remained on 
treatment without clinical symptoms. All changes returned 
to normal at follow-up. In the THA study with once-daily 
administration of rivaroxaban (Eriksson et al 2006b), ALT 
or AST levels 3x ULN occurred in 7.1% and 7.1% of 
patients in the enoxaparin group compared with 3.0%–5.4% 
and 3.4%–6.2%, respectively, in the rivaroxaban groups. 
One patient treated with rivaroxaban 30 mg od for 7 days 
showed elevation of ALT 3x ULN and bilirubin 2x 
ULN 3 h after the ﬁ  rst drug administration. Both returned to 
normal at follow-up despite continued treatment. In a patient 
treated with rivaroxaban 10 mg od for 7 days, who eventu-
ally had a diagnosis of cholecystolithiasis, liver enzymes 
continued to rise after treatment cessation. In general, 
none of the studies showed any dose-dependency between 
rivaroxaban and increased liver parameters. Based on the 
ﬁ  ndings in the phase II program, however, it was not pos-
sible to determine whether there was a relationship between 
rivaroxaban and liver function impairment. Another open 
question after the phase II program was whether there was 
an increased risk of liver function impairment when rivar-
oxaban was given for thromboprophylaxis on an extended 
basis (up to 35 days), which was seen with ximelagatran 
(Kenne et al 2008).
Rationale for dose selection
In general, when a dose of any new anticoagulant has to be 
selected both efﬁ  cacy and safety should be taken into con-
sideration and a perfect balance is preferable. A population 
analysis was performed to compare the pharmacodynamics 
and pharmacokinetics of total daily doses of rivaroxaban 
of 5 mg, 10 mg, and 20 mg (Mueck et al 2006) using blood 
samples collected in the previously mentioned clinical phase 
II studies with once- or twice-daily dosing of rivaroxaban in 
patients undergoing THA (Eriksson et al 2006a, b). It was 
found that both maximum and minimum plasma concentra-
tions of rivaroxaban were lower after once-daily compared 
with twice-daily administration, but with overlapping 90% 
conﬁ  dence intervals. The pharmocokinetic properties of riva-
roxaban were found to be independent of the dosing regimen 
(Mueck et al 2006). In a blinded, placebo-controlled study 
in healthy volunteers, the effect of body weight (BW) and 
gender on the efﬁ  cacy and safety of a single 10 mg dose of 
rivaroxaban were assessed. The study showed no inﬂ  uence 
of extreme BW ( 120 kg) compared with normal BW 
(70–80 kg) on the Cmax of rivaroxaban, but it was increased 
by 24% in female subjects weighing 50 kg or less, resulting 
in a 15% prolongation of PT; however, this result had no 
clinical relevance. In addition, because gender or BW did 
not affect the area under the curve, dose adjustment would 
not be necessary (Kubitza et al 2007b). Based on the rates 
of the primary safety end-point in the last phase II study, it 
was obvious that total daily rivaroxaban doses of 5–10 mg 
were comparable to those seen in the enoxaparin group, 0.7% 
and 0.8%, respectively, vs 1.9%. On the contrary, the rates 
of the primary efﬁ  cacy end-point in these two rivaroxaban 
groups were clearly lower compared with enoxaparin, 14.9 
and 10.6, respectively vs 25.2% (Table 2) (Eriksson 2006b). 
Summarizing these results, it was decided that a once-daily 
dosage of 10 mg of rivaroxaban should be studied in the 
phase III program in orthopedic surgery.
Phase III program
The clinical phase III program in orthopedic surgery was 
given the acronym: RECORD (Regulation of Coagulation 
in major Orthopaedic surgery reducing the Risk of DVT 
and PE). The RECORD program consists of the four clinical 
prophylaxis studies presented in Table 3. All studies were 
prospective, double blind, randomized studies comparing 
the antithrombotic efﬁ  cacy and safety of rivaroxaban 10 
mg given orally once daily and enoxaparin 40 mg once 
daily or 30 mg twice daily in patients undergoing THA or 
TKA. RECORD 1 and RECORD 2 were performed in THA Vascular Health and Risk Management 2008:4(4) 860
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patients and 40 mg once daily of enoxaparin was used for 
comparison in both studies. In RECORD 1 both prophy-
lactic regimens were given for a total duration of 35 ± 4 
days (long term), whereas in RECORD 2 only rivaroxaban 
was given long term compared with enoxaparin which was 
given for 10–14 days (short term) (Table 3), because it is 
not universally accepted to use long-term prophylaxis after 
THA in spite of the recommendation in the ACCP guide-
lines (Geerts at el 2004). RECORD 3 and RECORD 4 were 
performed in TKA patients with short-term duration (10–14 
days) of both regimens, because long-term prophylaxis is not 
recommended after TKA (Geerts et al 2004). In RECORD 
3, 10 mg of rivaroxaban once daily started 6–8 h after sur-
gery was compared with 40 mg of enoxaparin started in the 
evening before surgery, whereas in RECORD 4 enoxaparin 
30 mg twice daily started 12–24 h after surgery was used 
in the comparator arm (Table 3). The efﬁ  cacy results of 
the RECORD studies are presented in Tables 4 and 5. In 
all studies rivaroxaban was signiﬁ  cantly more effective in 
reducing the primary efﬁ  cacy end-point, the composite of 
the incidence of any DVT (proximal and/or distal), nonfatal 
symptomatic, objectively conﬁ  rmed PE and all cause deaths 
and major VTE, the composite of proximal DVT, PE, and 
VTE-related death, compared with enoxaparin (Table 4). In 
the RECORD 2 and RECORD 3 studies, rivaroxaban also sig-
niﬁ  cantly reduced the incidence of symptomatic VTE events 
compared with enoxaparin (Table 5), which are important 
clinical observations. The safety (the incidence of major and/
or minor bleeding events) of rivaroxaban was comparable 
with enoxaparin in all the phase III studies (Table 6). The 
RECORD 4 study has been ﬁ  nalized very recently, but no 
results have been released yet. The liver safety parameters 
showed no important differences between rivaroxaban and 
enoxaparin, and no different action was observed on liver 
function when rivaroxaban was used for long-term prophy-
laxis in the RECORD 1 and RECORD 2 studies compared 
with short-term prophylaxis with rivaroxaban. A more 
detailed description of these results cannot be given because 
the studies have been published only in abstract form.
Patient-focused perspectives such 
as quality of life, patient satisfaction/
acceptability
The ideal antithrombotic is a drug with a broad therapeutic 
window in terms of efﬁ  cacy versus safety (bleeding), with a 
rapid onset and offset of action, with a high bioavailability and 
minimal food and drug interactions after oral administration, 
and predictable pharmacodynamics and pharmacokinetics with 
Table 4 Efﬁ  cacy results in the phase III studies of the RECORD program
Study title (reference) N (randomized) Primary efﬁ  cacy end-
pointa (major VTEb) %
Relative
risk reduction %
P-value
for difference
riva enox
RECORD 1
(Eriksson et al 2007c)
3135
(4541)
1.1
(0.2)
3.7
(2.0)
70
(88)
<0.001
(<0.001)
RECORD 2
(Kakkar et al 2007)
1723
(2509)
2.0
(0.6)
9.3
(5.1)
79
(88)
<0.001
(<0.001)
RECORD 3
(Lassen et al 2007b)
1702
(2531)
9.6
(1.0)
18.9
(2.6)
49
(62)
<0.001
(0.016)
aPrimary efﬁ  cacy end-point was the composite of the incidence of any deep vein thrombosis (DVT) (proximal and/or distal), nonfatal symptomatic, objectively conﬁ  rmed 
pulmonary embolism (PE) and all cause deaths.
bMajor venous thromboembolism (VTE): the composite of proximal DVT-, PE-, and VTE-related death.
Abbreviations: riva, rivaroxaban; enox, enoxaparin.
Table 3 Design of the double blind, randomized phase III prophylaxis 
studies in orthopedic surgery
Study title 
(reference)
Operation Doses (mg) Duration
of prophylaxis 
(days)
     riva enox riva enox
RECORD 1 
(Eriksson et al 
2007c)
 10  oda 40 odb 35 ± 4 35 ± 4
RECORD 2 
(Kakkar et al 
2007)
THA 10 oda 40 odb 35 ± 4 10–14
RECORD 3 
(Lassen et al 
2007b)
TKA 10 oda 40 odb 10–14 10–14
RECORD 4 TKA 10 oda 30 bidc 10–14 10–14
aStarted 6–8 h after surgery (tablets).
bStarted on the evening before surgery (injected subcutaneously).
cStarted 12–24 h after surgery (injected subcutaneously).
Abbreviations: THA, total hip arthroplasty; TKA, total knee arthroplasty; riva, 
rivaroxaban; enox, enoxaparin.Vascular Health and Risk Management 2008:4(4) 861
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no requirement for dose adjustment and coagulation monitor-
ing. For the patient, such a drug would be easy to handle in 
everyday life, and therefore patient acceptability would be 
easily obtained. When we consider the clinical behavior of 
rivaroxaban in phase II and III it seems that it comes close to 
this ideal. However, there are still some outstanding questions 
to be resolved, such as the inﬂ  uence of impaired renal function 
on drug safety, the lack of an antidote in case of a bleeding 
event, and patients with nausea and vomiting after surgery 
being unable to take the medication as planned, and patients 
with indwelling epidural catheters. Based on previous expe-
rience, the cost-effectiveness of a new drug compared with 
existing alternatives is also important for clinicians deciding 
whether to use a new drug. Competition from other new drugs 
on the market is also important. Dabigatran etexilate, an oral 
direct thrombin inhibitor, has recently been approved in Europe 
for thromboprophylaxis in orthopedic settings. In a recent 
prospective study, dabigatran etexilate was as effective and 
safe as enoxaparin 40 mg od in reducing the risk of VTE after 
THA (Eriksson et al 2007d). Within the near future it will be 
settled if both drugs will be approved and then only a direct 
comparison in a relevant clinical study can show which of the 
drugs that has the most proﬁ  table efﬁ  cacy and safety.
Conclusions, therapeutic potential
Rivaroxaban – an oral, direct FXa inhibitor – is a new com-
pound for VTE prophylaxis after orthopedic surgery. The drug 
has predictable pharmacokinetics and pharmacodynamics and 
needs no coagulation monitoring or dose adjustment. Results 
from phase II and phase III clinical studies have shown that 
rivaroxaban, at a once-daily dosage of 10 mg, has a signiﬁ  -
cantly better efﬁ  cacy and a comparable safety compared with 
enoxaparin in patients undergoing THA and TKA.
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